Florida Cancer Specialists Research to be Presented at European Society of Medical Oncology 2019 Congress

Global gathering showcases the latest advances in cancer care

Fort Myers, Fla., September 23, 2019 — Florida Cancer Specialists & Research Institute (FCS) will be well-represented at the upcoming European Society of Medical Oncology (ESMO) Congress, to be held in Barcelona, Spain, Sept. 27 – Oct. 1, 2019. Six FCS physicians are the authors and/or co-authors of ten cancer research studies that will be presented at the Congress.  With over 20,000 members world-wide, the ESMO Congress gathers oncologists, researchers, patient advocates and pharmaceutical representatives to share the latest cutting-edge developments and findings.

“We are extremely proud that research done through the FCS Phase 1 Drug Development Unit (DDU) in Sarasota and at FCS clinics throughout Florida is contributing to significant advances in cancer care,” said Dr. James A. Reeves Jr., director of FCS Research Operations.

Prechtl-Gordan-Reeves-2

Dr. Ivor Percent is the co-author of a study that will be presented at a session on genitourinary tumors and Dr. Gail Lynn Wright co-authored a study that will be presented at the metastatic breast cancer session.  Dr. Wright’s study will be published simultaneously at The Lancet Oncology, an independent, international journal publishing high quality, peer-reviewed research and news relevant to clinical cancer specialists worldwide.

The following FCS physician investigators will present their research results during poster discussions and/or presentations:

  • Dr. Judy Wang, who served as lead author and co-author of several studies that involved advanced solid tumors
  • Dr. Manish Patel, director of the FCS Drug Development Unit, who co-authored two Phase 1 studies with advanced solid tumors, as well as research findings from a Phase 2a clinical trial involving the treatment of patients with tumors
  • Dr. Lowell Hart, who co-authored studies on small-cell lung cancer and breast cancer
  • Dr. James A. Reeves Jr., who co-authored a study involving breast cancer

“To have six FCS physicians’ research studies being published and shared on this prestigious global stage confirms that FCS is at the forefront of new discoveries and findings that will expand and improve cancer treatment options for our patients and, indeed, all cancer patients,” said FCS CEO Brad Prechtl, MBA. “Our strategic partnership with Sarah Cannon, one of the leading clinical trial organizations in the world, enables us to offer access to more national clinical trials than any other oncology practice in the state of Florida.”

“We have participated in the development of more than 85% of new drugs approved for use in the past five years through our research centers and clinics, which are strategically located throughout the FCS statewide network,” added FCS President and Managing Physician Lucio Gordan, MD. “Florida Cancer Specialists’ research rivals that of most academic medical centers and is setting a national benchmark for community oncology. This means we can offer patients the most promising new drugs prior to FDA approval.”

The ESMO Congress 2019 will be the global stage for the exchange of potentially practice-changing data and multidisciplinary conversations that will spur transformative therapies against cancer. All of the study abstracts will be published online in the ESMO Congress 2019 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

###

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com

Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. In the past four years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, FCS is the largest privately held independent medical oncology/hematology practice in the country. With more than 230 physicians, 220 advanced practice registered nurses (APRN) and physician assistants (PA) and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings, close to home.

Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy.  Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

*Prior to approval

For More Information, Contact:
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer
SGlenn@FLCancer.com
(770) 365.6168

Michelle Robey, Director of Marketing & Communications
Michelle.Robey@FLCancer.com
(813) 767.9398